|
|
Vaccine Detail
|
VEGFR1-1084 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: VEGFR1-1084 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007141
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- FLT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: This is a peptide vaccine derived from HLA-A*2402/A*0201-restricted vascular endothelial growth factor receptor type 1 (VEGFR1) (Nagayama et al., 2010).
- Description: This is for Pancreatic Cancer (NCT00655785). A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity (Nagayama et al., 2010; NCIT_C77895).
|
| Host Response |
|
|
| References |
Nagayama et al., 2010: Nagayama H, Matsumoto K, Isoo N, Ohno H, Takahashi N, Nakaoka T, Shinozaki M, Watanabe M, Inoue Y, Nagamura F, Oyaizu N, Yamashita N. Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical journal of gastroenterology. 2010; 3(6); 307-317. [PubMed: 26190488].
NCIT_C77895: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77895]
NCT00655785: Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) [https://clinicaltrials.gov/ct2/show/NCT00655785]
|
|
